Published 2022-01-11
Hafizar Fakhri Rahman Rainier Rumanter Agus Rizal Ardy Hariandy Hamid Chaidir Arif Mochtar Rainy Umbas Sahat BRE Matondang


Objective: To evaluate the usage of MRI in prostate cancer staging, especially in nodal involvement (N-staging) and metastasis (M-staging) of prostate cancer. Methods: This is a systematic review and meta-analysis assessing role of MRI in nodal and metastasis staging of prostate cancer. Search of studies were done through search engine using Pubmed, Cochrane, and EBSCO Host and manual searching. Quality of eligible studies were assessed using a revised version of Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) and analyzed in pooled analysis according to nodal involvement or metastasis staging, modality of diagnosis used as the index test and gold standard used using STATA version 13. Results: Total 26 studies corresponding with study’s eligibility criteria were found. Overall, usage of MRI has a sensitivity of 47% (95% CI 35% - 60%; I2 83.08%) and a specificity of 93% (95% CI 89% - 96%, I2 82.21%) in nodal involvement staging of prostate cancer, while using of MRI in M-staging of prostate cancer shows a sensitivity of 94% (95% CI 86% - 97%) and a specificity of 99% (95% CI 97% - 99%). Using lymphotrophic superparamagnetic nanoparticle (LSN) - enhanced MRI gives higher sensitivity than using MRI without LSN for N-staging of prostate cancer. Conclusion: The usage of MRI in prostate cancer staging has a moderate sensitivity and relatively high specificity in detecting lymph node. Moreover, it plays an important role and even can be used as a modality of choice in assisting bone metastatic prostate cancer detection.



Magnetic Resonance Imaging, Prostate cancer, Staging


Bashir MN. Epidemiology of prostate cancer. Asian Pacific J Cancer Prev. 2015;16(13):5137–41.

Mottet N, Bellmunt J, Briers E. EAU - ESTRO - ESUR - SIOG Guidelines Prostate Cancer. European Association of Urology (EAU). 2017.

Mohler J, Lee R, Antonarakis ES, Arsmstrong A, D’Amico A, Davis B, et al. Prostate Cancer. Volume 2. National Comprehensive Cancer Network. 2018. Available from:

Bishoff J, Rastinehad A. Urinary tract imaging: basic principles of computed tomography, magnetic resonance imaging, and plain film. In: Wein A, Kavoussi L, Partin A, Peters C, editors. Campbell-Walsh Urology. 11th ed. Philadelphia: Elsevier; 2016.

Morrison, A. The Global Impact of Technetium-99m [Environmental Scan Issue 11]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2010.

Murphy GH, M. Ghai, S. Sreeharsha, B. The expanding role of MRI in prostate cancer. AJR. 2013;201(1):1229-38.

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Br Med J. 2015;4(1):1–9.

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J, et al. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Ann Intern Med. 2011;155:529–36.

Gupta M, Choudhury P, Hazarika D, Rawal S. A comparative study of 68 Gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: An initial experience. World J Nucl Med [Internet]. 2017;16(3):186.

Zugor V, Brandenstein MVON, Akbarov I. Preoperative Stating of Pelvic Lymph Nodes in Prostate Cancer Patients via Endorectal Magnetic Resonance Imaging. 2018;1765:1763–5.

Selnæs KM, Krüger-stokke B, Elschot M, Willoch F, Størkersen Ø, Langørgen S, et al. F-Fluciclovine PET / MRI for preoperative lymph node staging in high-risk prostate cancer patients. 2017;

Zhang Q, Zang S, Zhang C, Fu Y, Lv X, Zhang Q, et al. Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer. J Transl Med [Internet]. 2017;15(1):230.

Von Below C, Daouacher G, Wassberg C, Grzegorek R, Gestblom C, Sörensen J, et al. Validation of 3 T MRI including diffusion-weighted imaging for nodal staging of newly diagnosed intermediate- and high-risk prostate cancer. Clin Radiol. 2016;71(4):328–34.

Borley NC, Fabrin K, Sriprasad S, Mondaini N, Thompson PM, Muir GH, et al. Laparoscopic Pelvic Lymph Node Dissection Allows Significantly More Accurate Staging in “High-risk” Prostate Cancer Compared to MRI or CT. Scand J Urol Nephrol. 2003;37(5):382–6.

Pasoglou V, Michoux N, Peeters F, Larbi A, Tombal B, Selleslagh T, et al. Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease. Radiology. 2015;275(1):155–66.

Pinaquy J-B, De Clermont-Galleran H, Pasticier G, Rigou G, Alberti N, Hindie E, et al. Comparative effectiveness of [18F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer. Prostate [Internet]. 2015;75(3):323–31.

Van Den Bergh L, Lerut E, Haustermans K, Deroose CM, Oyen R, Isebaert S, et al. Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement. Urol Oncol Semin Orig Investig. 2015;33(3):109.e23-109.e31.

Pasoglou V, Larbi A, Collette L, Annet L, Jamar F, Machiels JP, et al. One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): Toward an upfront simplified “all-in-one” imaging approach? Prostate. 2014;74(5):469–77.

Heck MM, Souvatzoglou M, Retz M, Nawroth R, Kübler H, Maurer T, et al. Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2014;41(4):694–701.

Jeong IG, Lim JH, You D, Kim MH, Choi HJ, Kim JK, et al. Incremental value of magnetic resonance imaging for clinically high risk prostate cancer in 922 radical prostatectomies. J Urol [Internet]. 2013;190(6):2054–60.

Lecouvet FE, El Mouedden J, Collette L, Coche E, Danse E, Jamar F, et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol. 2012;62(1):68–75.

Budiharto T, Joniau S, Lerut E, Van Den Bergh L, Mottaghy F, Deroose CM, et al. Prospective evaluation of11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol. 2011;60(1):125–30.

Contractor K, Challapalli A, Barwick T, Winkler M, Hellawell G, Hazell S, et al. Use of [ 11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin Cancer Res. 2011;17(24):7673–83.

Eiber M, Beer AJ, Holzapfel K, Tauber R, Ganter C, Weirich G, et al. Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol. 2010;45(1):15–23.

Kim B, Breau RH, Papadatos D, Fergusson D, Doucette S, Cagiannos I, et al. Diagnostic accuracy of surface coil magnetic resonance imaging at 1.5 T for local staging of elevated risk prostate cancer. Can Urol Assoc J. 2010;4(4):257–62.

Heesakkers RA, Hövels AM, Jager GJ, van den Bosch HC, Witjes JA, Raat HP, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol. 2008;9(9):850–6.

Heebøll S, Solvig J, Borre M. Prostate cancer: To scan or not to scan for lymph node involvement? Scand J Urol Nephrol. 2007;41(6):501–6.

Wang L, Hricak H, Kattan MW, Schwartz LH, Eberhardt SC, Chen HN, et al. Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. Am J Roentgenol. 2006;186(3):743–8.

Harishinghani M, Barentsz J, Hahn P, Deserno W, Tabatabaei S, van de Kaa C, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348(25):2491–9.

Harisinghani MG, Barentsz JO, Hahn PF, Deserno W, de la Rosette J, Saini S, et al. MR Lymphangiography for Detection Of Minimal Nodal Disease In Patients With Prostate Cancer: Does Postcontrast imaging alone suffice for accurate characterization. Acad Radiol. 2002;66:2003–2003.

Woo S, Kim SY, Kim SH, Cho JY. Identification of bone metastasis with routine prostate MRI: A study of patients with newly diagnosed prostate cancer. Am J Roentgenol. 2016;206(6):1156–63.

Vargas HA, Schor-Bardach R, Long N, Kirzner AN, Cunningham JD, Goldman DA, et al. Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis. Abdom Radiol. 2017;42(1):271–7.

Venkitaraman R, Venkitaraman R, Cook G, Cook G, Dearnaley DP, Dearnaley DP, et al. Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. J Med Imaging Radiat Oncol. 2009;53:241–7.

Venkitaraman R, Cook GJR, Dearnaley DP, Parker CC, Huddart RA, Khoo V, et al. Does Magnetic Resonance Imaging of the Spine Have a Role in the Staging of Prostate Cancer? Clin Oncol. 2009;21(1):39–42.

Woo S, Suh CH, Kim SY, Cho JY, Kim SH. The Diagnostic Performance of MRI for Detection of Lymph Node Metastasis in Bladder and Prostate Cancer: An Updated Systematic Review and Diagnostic Meta-Analysis. AJR Am J Roentgenol. 2018 Mar;210(3):W95–109.

Wang SC, McCarthy LP, Mehdi S. Isolated Hepatic Metastasis from Prostate Carcinoma. Urol Case Reports [Internet]. 2017 Jan 6;10:51–3. Available from:

Jacobs MA, Macura KJ, Zaheer A, Antonarakis ES, Stearns V, Wolff AC, et al. Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. Acad Radiol. 2018;1–10.

Biederer J, Hintze C, Fabel M. MRI of pulmonary nodules: technique and diagnostic value. Cancer Imaging [Internet]. 2008 May 19;8(1):125–30. Available from:

Namasivayam S, Martin DR, Saini S. Imaging of liver metastases: MRI. Cancer Imaging [Internet]. 2007 Feb 1;7(1):2–9. Available from:

Fortuin AS, Smeenk RJ, Meijer HJM, Witjes AJ, Barentsz JO. Lymphotropic nanoparticle-enhanced MRI in prostate cancer: Value and therapeutic potential. Curr Urol Rep. 2014;15(3).

Saksena MA, Saokar A, Harisinghani MG. Lymphotropic nanoparticle enhanced MR imaging (LNMRI) technique for lymph node imaging. Eur J Radiol. 2006;58(3):367–74.

de Rooij M, Hamoen EHJ, Witjes JA, Barentsz JO, Rovers MM. Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. Eur Urol. 2016;70(2):233–45.

Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University